...
首页> 外文期刊>Evidence-based Preclinical Medicine >Anti‐inflammatory compounds to reduce infarct size in large‐animal models of myocardial infarction: A meta‐analysis
【24h】

Anti‐inflammatory compounds to reduce infarct size in large‐animal models of myocardial infarction: A meta‐analysis

机译:在大动物心肌梗死模型中使用抗炎化合物减少梗死面积:一项荟萃分析

获取原文
           

摘要

ABSTRACTTargeting the inflammatory response after myocardial infarction (MI) could potentially prevent infarct expansion, resulting in a preservation of cardiac function. Despite extensive testing in large-animal models of MI, anti-inflammatory therapeutics are not incorporated in daily clinical practice. Methodological review of the literature describing the effects of anti-inflammatory compounds in large-animal models of MI may provide useful insights into the reasons for the translational failure from preclinical to clinical studies. Moreover, systematic review of these preclinical studies may allow us to determine which anti-inflammatory agents have the greatest potential to successfully treat MI in the clinic and guide which preclinical setting appears most appropriate to test these future treatment strategies in. The current systematic review protocol provides a detailed description of the design of this systematic review of studies investigating the effects of anti-inflammatory compounds in large-animal models of MI.
机译:摘要针对心肌梗塞(MI)后的炎症反应可能潜在地防止梗塞扩大,从而保留心脏功能。尽管在大动物模型的MI中进行了广泛的测试,但抗炎治疗剂并未纳入日常的临床实践中。描述抗炎化合物在大动物模型的MI中的作用的文献的方法学评论可能为从临床前研究到临床研究导致翻译失败的原因提供有用的见解。此外,对这些临床前研究的系统评价可以使我们确定哪些抗炎药最有可能在临床上成功治疗MI,并指导哪种临床前环境似乎最适合测试这些未来的治疗策略。当前的系统评价方案提供了该系统综述的设计详细说明,该研究综述了抗炎化合物在MI大动物模型中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号